OncoSec Medical Obtains Allowance of Key Patent Application for Intratumoral Delivery of Plasmid IL-15

OncoSec Medical Inc. , a company developing DNA-based intratumoral cancer immunotherapies, announces that the United States Patent and Trademark Office has allowed claims covering a method of treating cancerous tumors with plasmid-encoded IL-15 and electroporation therapy to the tumor having a field strength of at least 700 V/cm.



from Content Keyword RSS http://ift.tt/1AaNRqU

via IFTTT